调强放疗联合同步化疗治疗中晚期食管癌的疗效观察

Clinical Observation of Intensity-Modulated Radiotherapy Combined with Concurrent Chemotherapy in Treatment of Advanced Esophageal Cancer

目的对调强放疗联合同步化疗在中晚期食管癌中的治疗效果。方法研究参与对象为我院2016年1月份到2017年4月份收纳的中晚期食管癌50例。采用随机数字表法分成两组,对照组25例,予以单纯放疗;实验组25例,予以调强放疗联同步化疗,并分析和比较两组的临床疗效以及预后情况。结果实验组的总有效率相比对照组要高,差异有统计学意义(P<0.05);实验组1、2年局控率相比对照组要高,差异有统计学意义(P<0.05),两组的生存率差异无统计学意义(P>0.05);实验组的不良反应率相比对照组高,差异有统计学意义(P<0.05)。结论对中晚期食管癌患者实施调强放疗联同步化疗实施治疗,可有效提高治疗效果,患者生存率提高,但不良反应率较高。

Objective To evaluate the efficacy of combined intensity radiotherapy and concurrent chemotherapy in patients with advanced esophageal cancer. Methods The study of 50 patients with advanced esophageal cancer from January 2016 to April 2017 were studied. Two groups were divided into two groups. In 25 patients, the modulated radiotherapy combined chemotherapy was set up as the experimental group. The treatment of the two groups was studied, and the clinical efficacy and prognosis of the two groups were analyzed and compared. Results The effective rate of the experimental group compared to the control group, the difference was statistically significant(P<0.05); the experimental group 1, 2 year local control rate compared with the control group, the difference was statistically significant(P<0.05), there was no significant difference in survival rate between the two groups(P>0.05); adverse reaction rate in experimental group compared to the the control group, the difference was statistically significant(P<0.05). Conclusion Intensity modulated radiotherapy combined with concurrent chemotherapy can effectively improve the effect of treatment and improve the survival rate of patients with advanced esophageal cancer, but the rate of adverse reactions is higher.